BPMC vs. CYTK, ITCI, JAZZ, ASND, IONS, OGN, BBIO, CERE, APLS, and VKTX
Should you be buying Blueprint Medicines stock or one of its competitors? The main competitors of Blueprint Medicines include Cytokinetics (CYTK), Intra-Cellular Therapies (ITCI), Jazz Pharmaceuticals (JAZZ), Ascendis Pharma A/S (ASND), Ionis Pharmaceuticals (IONS), Organon & Co. (OGN), BridgeBio Pharma (BBIO), Cerevel Therapeutics (CERE), Apellis Pharmaceuticals (APLS), and Viking Therapeutics (VKTX). These companies are all part of the "pharmaceutical preparations" industry.
Cytokinetics (NASDAQ:CYTK) and Blueprint Medicines (NASDAQ:BPMC) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, community ranking, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.
Blueprint Medicines has higher revenue and earnings than Cytokinetics. Blueprint Medicines is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Cytokinetics had 12 more articles in the media than Blueprint Medicines. MarketBeat recorded 29 mentions for Cytokinetics and 17 mentions for Blueprint Medicines. Cytokinetics' average media sentiment score of 0.63 beat Blueprint Medicines' score of 0.39 indicating that Blueprint Medicines is being referred to more favorably in the news media.
Cytokinetics received 256 more outperform votes than Blueprint Medicines when rated by MarketBeat users. Likewise, 79.24% of users gave Cytokinetics an outperform vote while only 67.84% of users gave Blueprint Medicines an outperform vote.
Cytokinetics has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500. Comparatively, Blueprint Medicines has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500.
Cytokinetics currently has a consensus price target of $81.60, suggesting a potential upside of 37.07%. Blueprint Medicines has a consensus price target of $102.65, suggesting a potential downside of 2.20%. Given Blueprint Medicines' stronger consensus rating and higher possible upside, research analysts plainly believe Cytokinetics is more favorable than Blueprint Medicines.
Blueprint Medicines has a net margin of -102.15% compared to Blueprint Medicines' net margin of -14,141.74%. Blueprint Medicines' return on equity of 0.00% beat Cytokinetics' return on equity.
Summary
Cytokinetics beats Blueprint Medicines on 10 of the 17 factors compared between the two stocks.
Get Blueprint Medicines News Delivered to You Automatically
Sign up to receive the latest news and ratings for BPMC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BPMC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Blueprint Medicines Competitors List
Related Companies and Tools
